GlassScriptPhysician profile
Carlos Bejar
NPI 1619073087
$529,884.39
in general payments reported to CMS, 2019-2025
36 companies · $64K in 2025
The $64K reported for 2025 was more than what 99% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,539 · 2020: $3,767 · 2021: $55K · 2022: $177K · 2023: $119K · 2024: $101K · 2025: $64K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $240K · Travel and Lodging: $23K · Food and Beverage: $16K · Consulting Fee: $5,994 · Education: $196.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $240,139.88 |
| Travel and Lodging | $22,581.60 |
| Food and Beverage | $15,926.86 |
| Consulting Fee | $5,994.47 |
| Education | $196.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $296,569.85 | 2019-2025 | Farxiga, Lokelma, Flumist Quadrivalent |
| Bayer Healthcare Pharmaceuticals INC. | $101,657.97 | 2021-2025 | |
| Novo Nordisk INC | $60,397.56 | 2022-2025 | Ozempic, Wegovy |
| Vifor Pharma, INC. | $35,665.07 | 2019-2025 | Veltassa, Korsuva |
| Amgen INC. | $13,709.12 | 2019-2025 | Tavneos, Krystexxa |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $7,838.64 | 2019-2024 | |
| Akebia Therapeutics INC | $4,377.21 | 2019-2025 | Vafseo |
| Otsuka America Pharmaceutical, INC. | $1,918.53 | 2019-2025 | Jynarque |
| Mallinckrodt Hospital Products INC. | $1,056.50 | 2020-2025 | Acthar, Terlivaz |
| Travere Therapeutics, INC. | $641.00 | 2022-2025 | |
| Ani Pharmaceuticals, INC. | $609.15 | 2023-2025 | Purified Cortrophin Gel |
| Novartis Pharmaceuticals Corporation | $591.42 | 2019-2025 | |
| Opko Pharmaceuticals, LLC | $453.22 | 2019-2025 | Rayaldee |
| Calliditas Therapeutics US INC. | $437.66 | 2022-2025 | Tarpeyo |
| Glaxosmithkline, LLC. | $421.20 | 2021-2025 | Benlysta, Jesduvroq, Arexvy |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nxstage Medical, INC. | $397.10 | 2020-2024 | |
| Alexion Pharmaceuticals, INC. | $392.08 | 2019-2025 | Ultomiris, Soliris |
| Boehringer Ingelheim Pharmaceuticals, INC. | $340.99 | 2023-2025 | Jardiance |
| Horizon Therapeutics Plc | $339.62 | 2021-2023 | Krystexxa |
| Aurinia Pharma U.S., INC. | $336.19 | 2021-2025 | Lupkynis |
| Merck Sharp & Dohme LLC | $290.92 | 2021-2023 | Verquvo |
| Mallinckrodt Enterprises LLC | $212.55 | 2019 | |
| Medtronic, INC. | $195.91 | 2025 | Ellipsys Vascular Access System |
| Fresenius USA Marketing, INC. | $164.46 | 2019-2025 | Velphoro |
| Kyowa Kirin, INC. | $156.13 | 2023-2025 | Crysvita |
| Bard Peripheral Vascular, INC. | $138.94 | 2019 | |
| Baxter Healthcare | $131.86 | 2019-2024 | Renal - Extraneal Solution |
| Ardelyx, INC. | $87.17 | 2024-2025 | Ibsrela |
| Alnylam Pharmaceuticals INC. | $80.99 | 2023-2025 | Oxlumo, Givlaari |
| Scpharmaceuticals INC. | $76.17 | 2024-2025 | |
| Lilly USA, LLC | $52.89 | 2023-2025 | Jardiance |
| Gastroklenz, INC. Dba Cloudcath | $46.03 | 2023 | |
| Arbor Pharmaceuticals, INC. | $34.70 | 2019-2021 | |
| Angiodynamics, INC. | $24.19 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $23.82 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.58 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carlos Bejar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.